| Source: |
| Type: antiapoptosis protein |
| Survivin, BIRC5 (Baculoviral IAP Repeat Containing 5) is a potent anti-apoptosis protein that is differentially expressed in cancer and therefore constitutes an important anti-cancer target [49]. Moreover, high expression of survivin plays important role in resistance to chemo- and radiotherapy and has been shown to be related to unfavorable outcome for medulloblastomas. "Survivin" is a protein that plays a crucial role in regulating cell division and inhibiting apoptosis (programmed cell death). It is part of the inhibitor of apoptosis (IAP) family and is often overexpressed in various types of cancer. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 581- | Api, | Cisplatin, | The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy |
| - | in-vitro, | Pca, | CD44+ |
| 208- | Api, | Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | DU145 |
| 2603- | Ba, | Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2754- | BetA, | Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors |
| - | in-vitro, | Pca, | LNCaP |
| 4935- | PEITC, | Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo |
| - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | PC3 |
| - | in-vitro, | Pca, | pCSCs |
| - | in-vitro, | Pca, | CD44+ | - | in-vitro, | NA, | CD133+ | - | in-vitro, | NA, | PC3 | - | in-vitro, | NA, | LNCaP |
| 5123- | Sal, | Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HEK293 |
| 3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
| - | in-vitro, | Pca, | PC3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:299 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid